Table of Contents Table of Contents
Previous Page  115 / 916 Next Page
Show Menu
Previous Page 115 / 916 Next Page
Page Background

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S106–S169


group (Pregabalin + antidepressant, 21 patients). Patients also had

comorbid diagnoses as follows: F 41.1, F 32, F 33 or F 34. Assess-

ment was done by 100mm Visual analogue scale (VAS) and by

Clinical Global Impression Scale (CGI). Within both groups there

was a statistically significant improvement measured by VAS and

CGI scales in all repeated measurements, except for the CGI scale

in both groups between the second and ninth month where there

was no statistical difference. There were no statistically significant

differences between CG and EG on both scales either in the begin-

ning or in repeated measurements. There was no difference in the

effects of the drugs between EG and CG on both scales- VAS & CGI.

Pregabalin as mono or as an adjuvant therapy had equally good

efficiency in patients with SD who had partial response on various

antidepressants therapy after long-term treatment.

Disclosure of interest

Results from part of this trial were pub-

lished as abstract in european psychiatry, Volume 30. Supplement

1, 28–31 March 2015, Pages 534 – “Somatoform Disorders-a

New Target for Pregabalin”,



Dissociation and therapy of depressive

and anxiety disorders with or without

personality disorders

J. Prasko

1 ,

, A. Grambal


, Z. Sigmundova


, P. Kasalova



D. Kamaradova


, K. Vrbova


, M. Ociskova


, M. Holubova



K. Latalova


, M. Zatkova


, M. Slepecky


, A. Kotianova



University Hospital Olomouc, Department of Psychiatry, Olomouc,

Czech Republic


Faculty of Social Science and Health Care- Constantine the

Philosopher University in Nitra, Slovak Republic, Department of

Psychology Sciences, Nitra, Slovak Republic

Corresponding author.


Goal of the study was to analyze the impact of dis-

sociation on the treatment of the patients with anxiety/neurotic

spectrum and depressive disorders, and with or without personal-

ity disorders.


The sample consisted of inpatients who met the ICD-

10 criteria for the Depressive disorder, Panic disorder, GAD, Mixed

anxiety-depressive disorder, Agoraphobia, Social phobia, OCD,

PTSD, Adjustment disorders, dissociative/conversion disorders,

Somatoform disorder or other anxiety/neurotic spectrum disor-

der. The participants completed Beck Depression Inventory, Beck

Anxiety Inventory, subjective version of clinical global impression-

severity, Sheehan Patient-Related Anxiety Scale, and Dissociative

Experience Scale, at the start and the end of the therapeutic pro-



The total of 840 patients with anxiety or depressive

spectrum disorders, who were resistant to pharmacological treat-

ment in outpatients basis and were referred for hospitalization

for the six-week complex therapeutic program, were enrolled in

this study. Six hundred and six of themwere statistically analyzed.

The patients’ mean ratings on all measurements were significantly

reduced during the treatment. The patients without comorbid

personality disorder improved significantly more than patients

with comorbid personality disorder in the reduction of depres-

sive symptoms. However, there were no significant differences in

change of anxiety levels and severity of the disorder between the

patients with and without personality disorders. The higher degree

of dissociation at the beginning of the treatment predicted minor

improvement. The higher therapeutic change was connected to the

greater reduction of the dissociation level.


Dissociation presents an important factor influenc-

ing treatment effectiveness in the treatment-resistant patients

with anxiety/depression with or without personality disorders.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Pharmacogenetic association between

glutamatergic genes and sri treatment

response in obsessive compulsive


T. Shukla

1 ,

, R.M.J. Jabeen Taj


, K. Kulkarni


, P. Shetty



B. Viswanath


, M. Purushottam


, Y.C. Reddy


, S. Jain



King George’s Medical University, Psychiatry, Lucknow, India


Centre de Recherche du CHU Sainte-Justine, université de Montréal,

Montreal, Canada


National Institute of Mental Health and Neurosciences, Psychiatry,

Bangalore, India


Cairns and Hinterland Hospital and Health Service, Psychiatry,

Melbourne, Australia

Corresponding author.


Pharmacogenetic studies in obsessive-compulsive

disorder (OCD) primarily focussing on serotonergic and dopami-

nergic polymorphisms, provided inconsistent findings. There is

recent evidence for glutamatergic abnormalities in OCD.


Examine the association glutamatergic genes with sero-

tonin reuptake inhibitor (SRI) response in OCD.


To study pharmacogenetic association between

SLC1A1 and GRIN2B polymorphisms with SRI response in OCD.


DSM-IV OCD patients were recruited from a specialty

OCD clinic and evaluated using the Yale-Brown obsessive compul-

sive scale (YBOCS), Mini International Neuropsychiatric Interview

(MINI) plus, Clinical Global Impression scale (CGI). They were

subsequently reassessed with YBOCS and CGI. To study extreme

phenotypes, we included only full responders (> 35% YBOCS

improvement and CGI-I score of 1 or 2) to any SRI (


= 191) and

non-responders (< 25% YBOCS improvement and CGI-I score


to adequate trial of at least two SRIs (


= 84). Partial responders

were excluded. Genotyping was performed using an ABI9700 PCR



Genotype frequencies did not deviate significantly from

the values predicted by the Hardy-Weinberg equation. Case-

control association analyses revealed no significant association

between genotype/allele frequencies with SRI response.


Our data does not show any association between

polymorphisms in glutamatergic genes and SRI response in OCD

though such associations have been found in other studies. More

SNP’s in the same gene could be responsible for the pharma-

cogenetic associations. More homogenous sample considering

symptom dimensions and other phenotypic variables may be

needed. It may be critical to go beyond “usual suspect” candi-

date gene research. In this regard, a novel approach to identify SRI

response biomarkers is the use of cellular models.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Long term effect of cognitive

behavioral therapy in patients with

health anxiety

K.E. Veddegjaerde

University of Bergen, Klinisk Institutt 2, Ålesund, Norway


Cognitive-behavioral therapy (CBT) has been found

to be an effective treatment of excessive health anxiety (HA), but

the long-term effect over 18months has not been examined.